Similarly, while Egfr homodimers may not play a tumor maintenance role in previously untreated alveolar rhabdomyosarcoma, the possibility remains that refractory (chemotherapy or kinase inhibitor resistant) tumors may still in fact be driven by Egfr tyrosine kinase receptor signaling. This evidence concerns the gene NTRK1 and alveolar rhabdomyosarcoma.